Document is current
Any future updates will be listed below
-
Authors
Sakuma, Kensuke
Tsubooka-Yamazoe, Noriko
Hashimoto, Kiyohiro
Sakai, Nozomu
Asano, Shinya
Watanabe-Matsumoto, Saori
Watanabe, Takeshi
Saito, Bunnai
Matsumoto, Hirokazu
Ueno, Hikaru
Ito, Ryo
Toyoda, Taro
-
Funding
Funding for this research was provided by:
Takeda-CiRA Joint Program for iPS Cell Applications
iPS Cell Research Fund
- License Information
-
More Information
Article History
Received: 3 July 2022
Accepted: 8 December 2022
First Online: 5 January 2023
Declarations
:
: The use of the iPSC line was approved by the Ethical Review Committee of the Shonan Health Innovation Park (Fujisawa, Kanagawa, Japan) and Kyoto University (#CiRA18-27). The animal experiments in this study were approved by the Institutional Animal Care and Use Committee of the Shonan Health Innovation Park (Shonan iPark), Takeda Pharmaceutical Company.
: Written informed consent was obtained from the HLA homozygous donors in hiPSC stock project for publication of this study. A copy of written consent is available for review by the Editor-in-Chief of this journal.
: Dr. Toyoda is a scientific advisor with advisory fee for Orizuru Therapeutics. Dr. Watanabe serves as a toxicological consultant for Orizuru but with no compensation. Drs. Sakuma, Yamazoe, Ueno, and Ito are employees of Orizuru. The remaining authors declare that they have no competing interests.
